Lipid phosphatases in the regulation of T cell activation: Living up to their PTEN-tial

Immunological Reviews

Volumn 192, Issue , 2003, Pages 80-97

  Seminario, Maria Cristina ^a   Wange, Ronald L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; INOSITOL; ITK PROTEIN; LIPID PHOSPHATASE; PHOSPHATASE; PHOSPHATE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE C; PHOSPHOLIPID; PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C ZETA; RECEPTOR; SERINE; T LYMPHOCYTE RECEPTOR; TEC PROTEIN; THREONINE; TYROSINE; UNCLASSIFIED DRUG; VAV PROTEIN;

AMINO ACID SEQUENCE; CATALYSIS; CELL MEMBRANE; CONFORMATIONAL TRANSITION; HUMAN; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOLS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

EID: 0037564493     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00013.x     Document Type: Review

References (198)

1. Ward SG, Cantrell DA. Phosphoinositide 3-kinases in T lymphocyte activation. Curr Opin Immunol 2001;13:332-338.
2. Vanhaesebroeck B, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2002;70:535-602.
3. Pawson T, Raina M, Nash P. Interaction domains: from simple binding events to complex cellular behavior. FEBS Lett 2002;513:2-10.
4. Bottomley MJ, Salim K, Panayotou G. Phospholipid-binding protein domains. Biochim Biophys Acta 1998;1436:165-183.
5. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999;11:219-225.
6. Rebecchi MJ, Scarlata S. Pleckstrin homology domains: a common fold with diverse functions. Annu Rev Biophys Biomol Struct 1998;27:503-528.
7. Blomberg N, Baraldi E, Nilges M, Saraste M. The PH superfold: a structural scaffold for multiple functions. Trends Biochem Sci 1999;24:441-445.
8. Fruman DA, Rameh LE, Cantley LC. Phosphoinositide binding domains: embracing 3-phosphate. Cell 1999;97:817-820.
9. Chan TO, Rittenhouse SE, Tsichlis PN. Akt/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014.
10. Wishart MJ, Taylor GS, Dixon JE. Phoxy lipids: revealing PX domains as phosphoinositide binding modules. Cell 2001;105:817-820.
11. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999;274:8347-8350.
12. Bae YS, Cantley LG, Chen CS, Kim SR, Kwon KS, Rhee SG. Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:4465-4469.
13. Ward SG, Ley SC, MacPhee C, Cantrell DA. Regulation of D-3 phosphoinositides during T cell activation via the T cell antigen receptor/CD3 complex and CD2 antigens. Eur J Immunol 1992;22:45-49.
14. Thompson PA, Gutkind JS, Robbins KC, Ledbetter JA, Bolen JB. Identification of distinct populations of PI-3 kinase activity following T-cell activation. Oncogene 1992;7:719-725.
15. Carrera AC, Rodriguez-Borlado L, Martinez-Alonso C, Merida I. T cell receptor-associated alpha-phosphatidylinositol 3-kinase becomes activated by T cell receptor cross-linking and requires pp56lck. J Biol Chem 1994;269:19435-19440.
16. Ueda Y, et al. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity m the regulation of T cell IL-2 secretion. Int Immunol 1995;7:957-966.
17. Truitt KE, Hicks CM, Imboden JB. Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J Exp Med 1994;179:1071-1076.
18. Prasad KV, et al. T-cell antigen CD28 interacts wink the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA 1994; 91:2834-2838.
19. Pages F, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994;369:327-329.
20. Stein PH, Fraser JD, Weiss A. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase. Mol Cell Biol 1994;14:3392-3402.
21. August A, Dupont B. CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase. Int Immunol 1994;6:769-774.
22. Okkenhaug K, Rottapel R. Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction. J Biol Chem 1998;273:21194-21202.
23. Osman N, Turner H, Lucas S, Reif K, Cantrell DA. The protein interactions of the immunoglobulin receptor family tyrosine-based activation motifs present in the T cell receptor zeta subunits and the CD3 gamma, delta and epsilon chains. Eur J Immunol 1996;26:1063-1068.
24. de Aos I, et al. Tyrosine phosphorylation of the CD3-epsilon subunit of the T cell antigen receptor mediates enhanced association with phosphatidylinositol 3-kinase in Jurkat T cells. J Biol Chem 1997;272:25310-25318.
25. Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998;92:83-92.
26. Bruyns E, et al. T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane. J Exp Med 1998;188:561-575.
27. Fukazawa T, et al. T cell activation-dependent association between the p85 subunit of the phosphatidylinositol 3-kinase and Grb2/ phospholipase C-gamma 1-binding phosphotyrosyl protein pp36/38. J Biol Chem 1995;270:20177-20182.
28. Genot E, Reif K, Beach S, Kramer I, Cantrell D. p21 ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB mediated signaling pathways in T lymphocytes. Oncogene 1998;17:1731-1738.
29. Genot EM, Arrieumerlou C, Ku G, Burgering BM, Weiss A, Kramer IM. The T-cell receptor regulates Akt (protein kinase B) via a pathway involving Rac1 and phosphatidylinositide 3-kinase. Mol Cell Biol 2000;20:5469-5478.
30. Tolias KF, Cantley LC, Carpenter CL. Rho family GTPases bind to phosphoinositide kinases. J Biol Chem 1995;270:17656-17659.
31. Zheng Y, Bagrodia S, Cerione RA. Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J Biol Chem 1994;269:18727-18730.
32. Chong LD, Traynor-Kaplan A, Bokoch GM, Schwartz MA. The small GTP-binding protein Rho regulates a phosphatidylinositol 4-phosphate 5-kinase in mammalian cells. Cell 1994;79:507-513.
33. Remillard B, et al. Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J Biol Chem 1991;266:14167-14170.
34. Gu H, et al. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol 2000;20:7109-7120.
35. Gadina M, et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J Biol Chem 2000;275:26959-26966.
36. Sotsios Y, Ward SG. Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunol Rev 2000;177:217-235.
37. Taichman R, Merida I, Torigoe T, Gaulton GN, Reed JC. Evidence that protein tyrosine kinase p56-Lck regulates the activity of phosphatidylinositol-3′-kinase in interleukin-2-dependent T-cells. J Biol Chem 1993;268:20031-20036.
38. Von Willebrand M, Baier G, Couture C, Burn P, Mustelin T. Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase. Eur J Immunol 1994;24:234-238.
39. Prasad KV, et al. Regulation of CD4-p56lck-associated phosphatidylinositol 3-kinase (PI 3-kinase) and phosphatidylinositol 4-kinase (PI 4-kinase). Philos Trans R Soc London B Biol Sci 1993;342:35-42.
40. Cai YC, Cefai D, Schneider H, Raab M, Nabavi N, Rudd CE. Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity 1995;3:417-426.
41. Eder AM, Dominguez L, Franke TF, Ashwell JD. Phosphoinositide 3-kinase regulation of T cell receptor-mediated interleukin-2 gene expression in normal T cells. J Biol Chem 1998;273:28025-28031.
42. Hutchcroft JE, Bierer BE. Signaling through CD28/CTLA-4 family receptors puzzling participation of phosphatidylinositol-3 kinase. J Immunol 1996;156:4071-4074.
43. Hutchcroft JE, Franklin DP, Tsai B, Harrison-Findik D, Varticovski L, Bierer BE. Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor. Proc Natl Acad Sci USA 1995;92:8808-8812.
44. Lu Y, Phillips CA, Trevillyan JM. Phosphatidylinositol 3-kinase activity is not essential for CD28 costimulatory activity in Jurkat T cells: studies with a selective inhibitor, wortmannin. Eur J Immunol 1995;25:533-537.
45. Truitt KE, Shi J, Gibson S, Segal LG, Mills GB, Imboden JB. CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. J Immunol 1995;155:4702-4710.
46. Shan X et al. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 2000;20:6945-6957.
47. Astoul E, Edmunds C, Cantrell DA, Ward SG. PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol 2001;22:490-496.
48. Pratt JC, et al. Cutting edge: gab2 mediates an inhibitory phosphatidylinositol 3′-kinase pathway in T cell antigen receptor signaling. J Immunol 2000;165:4158-4163.
49. Borlado LR, et al. Increased phosphoinositide 3-kinase activity reduces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000;14:895-903.
50. Fruman DA, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 1999;283:393-397.
51. Suzuki H, et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 1999;283:390-392.
52. Ueki K, et al. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2002;99:419-424.
53. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999;274:10963-10968.
54. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002;13:169-172.
55. Okkenhaug K, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-1034.
56. Sasaki T, et al. Function of PI3Kgaamma in thymocyte development T cell activation, and neutrophil migration. Science 2000;287:1040-1046.
57. Hirsch E, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000;287:1049-1053.
58. Harada Y, et al. Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. J Immunol 2001;166:3797-3803.
59. Okkenhaug K, et al. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol 2001; 2:325-332.
60. Yang WC, Collette Y, Nunes JA, Olive D. Tec kinases: a family with multiple roles in immunity. Immunity 2000;12:373-382.
61. Takesono A, Finkelstein LD, Schwartzberg PL. Beyond calcium: new signaling pathways for Tec family kinases. J Cell Sci 2002; 115:3039-3048.
62. Miller AT, Berg LJ. New insights into the regulation and functions of Tec family tyrosine kinases in the immune system. Curr Opin Immunol 2002;14:331-340.
63. van Leeuwen JE, Samelson LE. T cell antigen-receptor signal transduction. Curr Opin Immunol 1999;11:242-248.
64. Wange RL. LAT, the linker for activation of T cells: a bridge between T cell specific and general signaling pathways. Sci STKE 2000;2000:RE1.
65. Shan X, Wange RL. Itk/Emt/Tsk activation in response to CD3 cross-linking in Jurkat T cells requires ZAP-70 and Lat and is independent of membrane recruitment. J Biol Chem 1999;274:29323-29330.
66. Ching KA, Grasis JA, Tailor P, Kawakami Y, Kawakami T, Tsoukas CD. TCR/CD3-Induced activation and binding of Emt/Itk to linker of activated T cell complexes: requirement for the Src homology 2 domain. J Immunol 2000;165:256-262.
67. Su YW, Zhang Y, Schweikert J, Koretzky GA, Reth M, Wienands J. Interaction of SLP adaptors with the SH2 domain of Tec family kinases. Eur J Immunol 1999;29:3702-3711.
68. Lewis CM, Broussard C, Czar MJ, Schwartzberg PL. Tec kinases: modulators of lymphocyte signaling and development. Curr Opin Immunol 2001;13:317-325.
69. Yang WC, Ching KA, Tsoukas CD, Berg LJ. Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. J Immunol 2001;166:387-395.
70. Woods ML, Kivens WJ, Adelsman MA, Qiu Y, August A, Shimizu Y. A novel function for the Tec family tyrosine kinase Itk in activation of beta 1 integrins by the T-cell receptor. EMBO J 2001; 20:1232-1244.
71. Miller AT, Berg LJ. Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase. J Immunol 2002;168:2163-2172.
72. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000;346:561-576.
73. Toker A. Phosphoinositides and signal transduction. Cell Mol Life Sci 2002;59:761-779.
74. Belham C, Wu S, Avruch J. Intracellular signalling: PDK1 - a kinase at the hub of things. Curr Biol 1999;9:R93-R96.
75. Alessi DR, et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 1997;7:776-789.
76. Anderson KE, Coadwell J, Stephens LR, Hawkins PT. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr Biol 1998;8:684-691.
77. Currie RA, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositidedependent protein kinase-1. Biochem J 1999;337:575-583.
78. Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell 2000;103:185-188.
79. Alessi DR, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-6551.
80. Balendran A, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999;9:393-404.
81. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000;275:8271-8274.
82. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-664.
83. Scheel-Toellner D, et al. Cytokine-mediated inhibition of apoptosis in non-transformed T cells and neutrophils can be dissociated from protein kinase B activation. Eur J Immunol 2002;32:486-493.
84. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 2001;268:487-498.
85. Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin Immunol 2002;14:19-26.
86. Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 2002;168:2729-2736.
87. Lafont V, Astoul E, Laurence A, Liautard J, Cantrell D. The T cell antigen receptor activates phosphatidylinositol 3-kinase-regulated serine kinases protein kinase B and ribosomal S6 kinase 1. FEBS Lett 2000;486:38-42.
88. Parry R, Smith G, Reif K, Sansom DM, Ward S. Activation of the PI3K effector protein kinase B following ligation of CD28 or Fas. Biochem Soc Trans 1997;25:S589.
89. Parry RV, Reif K, Smith G, Sansom DM, Hemmings BA, Ward SG. Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. Eur J Immunol 1997;27:2495-2501.
90. Reif K, Burgering BM, Cantrell DA. Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70, S6 kinase. J Biol Chem 1997;272:14426-14433.
91. Jones RG, et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000;191:1721-1734.
92. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999;9:601-604.
93. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 2002;22:5962-5974.
94. Kane LP, Lin J, Weiss A. It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. Trends Immunol 2002; 23:413-420.
95. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999;19:4798-4805.
96. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin ASJ, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000;20:1626-1638.
97. Bauer B, Baier G. Protein kinase C and AKT/protein kinase B in CD4+ T-lymphocytes: new partners in TCR/CD28 signal integration. Mol Immunol 2002;38:1087-1099.
98. Parsons MJ, Jones RG, Tsao MS, Odermatt B, Ohashi PS, Woodgett JR. Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J Immunol 2001;167:42-48.
99. Masuyama N, Oishi K, Mori Y, Ueno T, Takahama Y, Gotoh Y. Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J Biol Chem 2001;276:32799-32805.
100. Pekarsky Y, et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc Natl Acad Sci USA 2001;98:3690-3694.
101. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001;276:6893-6896.
102. Avota E, et al. Disruption of Akt kinase activation is important for immunosuppression reduced by measles virus. Nat Med 2001;7:725-731.
103. Kazanietz MG. Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000;28:5-11.
104. Bauer B, et al. T cell expressed PKCtheta demonstrates cell-type selective function. Eur J Immunol 2000;30:3645-3654.
105. Coudronniere N, Villalba M, Englund N, Altman A. NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc Natl Acad Sci USA 2000;97:3394-3399.
106. Lin X, O'Mahony A, Mu Y, Geleziunas R, Greene WC. Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta. Mol Cell Biol 2000;20:2933-2940.
107. Sun Z, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000;404:402-407.
108. Bauer B, et al. Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells. J Biol Chem 2001;276:31627-31634.
109. Monks CR, Kupfer H, Tamir I, Barlow A, Kupfer A. Selective modulation of protein kinase C-theta during T-cell activation. Nature 1997;385:83-86.
110. Villalba M, et al. Translocation of PKC [theta] in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C. J Cell Biol 2002;157:253-263.
111. Genot EM, Parker PJ, Cantrell DA. Analysis of the role of protein kinase C-alpha, -epsilon, and -zeta in T cell activation. J Biol Chem 1995;270:9833-9839.
112. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 1902;84:203-229.
113. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997;275:1930-1934.
114. Welsh GI, Miyamoto S, Price NT, Safer B, Proud CG. T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J Biol Chem 1996;271:11410-11413.
115. Staal FJ, Burgering BM, van de Wetering M, Clevers HC. Tcf-1-mediated transcription in T lymphocytes, differential role for glycogen synthase kinase-3 in fibroblasts and T cells. Int Immunol 1999;11:317-323.
116. Diehn M, et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci USA 2002;99:11796-11801.
117. Ohteki T, et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 2000;192:99-104.
118. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. BioEssays 2002;24:65-71.
119. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997;16:3693-3704.
120. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-963.
121. Brennan P, Babbage JW, Thomas G, Cantrell D. p 70 (s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol 1999;19:4729-4738.
122. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JCJ, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15:5256-5267.
123. Sekulic A, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-3513.
124. Gonzalez-Garcia A, et al. A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation. J Biol Chem 2002;277:1500-1508.
125. Jascur T, Gilman J, Mustelin T. Involvement of phosphatidylinositol 3-kinase in NFAT activation in T cells. J Biol Chem 1997;272:14483-14488.
126. Schaeffer EM, et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 1999;284:638-641.
127. Acuto O, Cantrell D. T cell activation and the cytoskeleton. Annu Rev Immunol 2000;18:165-184.
128. Turner M, Billadeau DD. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol 2002;2:476-486.
129. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 2001;20:6372-6381.
130. Ma AD, Metjian A, Bagrodia S, Taylor S, Abrams CS. Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac guanosine exchange factor, and Rac. Mol Cell Biol 1998;18:4744-4751.
131. Das B, et al. Control of intramolecular interactions between the pleckstrin homology and Dbl homology domains of Vav and Sos1 regulates Rac binding. J Biol Chem 2000;275:15074-15081.
132. Gringhuis SI, de Leij LF, Coffer PJ, Vellenga E. Signaling through CD5 activates a pathway involving phosphatidylinositol 3-kinase, Vav, and Rac1 in human mature T lymphocytes. Mol Cell Biol 1998;18:1725-1735.
133. Han J, et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 1998;279:558-560.
134. Arudchandran R, et al. The Src homology 2 domain of Vav is required for its compartmentation to the plasma membrane and activation of c-Jun NH(2)-terminal kinase 1. J Exp Med 2000;191:47-60.
135. Abraham RT. Mutant T cell lines as model systems for the dissection of T cell antigen receptor signaling pathways. Immunol Res 2000;22:95-117.
136. Reynolds LF, et al. Vav1 transduces T cell receptor signals to the activation of phospholipase C-gammal via phosphoinositide 3-kinase-dependent and -independent pathways. J Exp Med 2002;195:1103-1114.
137. Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J 1998;17:414-422.
138. 2+ mobilization in antigen-stimulated mast cells. J Leukoc Biol 1999;65:321-329.
139. Ching TT, Hsu AL, Johnson AJ, Chen CS. Phosphoinositide 3-kinase facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4, 5-trisphosphate-sensitive Ca(2+) entry mechanism. J Biol Chem 2001;276:14814-14820.
140. Cuevas B, et al. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 1999;274:27583-27589.
141. Fang D, Wang HY, Fang N, Altman Y, Elly C, Liu YC. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 2001;276:4872-4878.
142. Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001;2:870-875.
143. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. Genes Dev 2000;14:505-520.
144. Seminario MC, Wange RL. Signaling pathways of D3-phosphoinositide-binding kinases in T cells and their regulation by PTEN. Semin Immunol 2002;14:27-36.
145. Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal 2002;14:285-295.
146. Helgason CD, et al. A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of b lymphocytes in SHIP -/- mice. J Exp Med 2000;191:781-794.
147. Edmunds C, Parry RV, Burgess SJ, Reaves B, Ward SG. CD28 stimulates tyrosine phosphorylation, cellular redistribution and catalytic activity of the inositol lipid 5-phosphatase SHIP. Eur J Immunol 1999;29:3507-3515.
148. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002;70:829-844.
149. Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
150. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-13378.
151. Myers MP, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 1998;95:13513-13518.
152. Lee JO, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999;99:323-334.
153. Gu J, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146:389-403.
154. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-1617.
155. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1999;274:20693-20703.
156. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999;285:2122-2125.
157. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-355.
158. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 1999;96:10182-10187.
159. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 2000;60:7033-7038.
160. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-5018.
161. Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 2001;61:4985-4989.
162. Birle D, et al. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol 2002;169:286-291.
163. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001;276:48627-48630.
164. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001;276:993-998.
165. Wu Y, et al. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem 2000;275:21477-21485.
166. Wu X, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 2000;97:4233-4238.
167. 2. J Biol Chem 2002;277:20336-20342.
168. Xu D, Rovira II, Finkel T. Oxidants painting the cysteine chapel: redox regulation of PTPs. Dev Cell 2002;2:251-252.
169. Rhee SG. Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol Med 1999;31:53-59.
170. Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M, Bookstein R. Adenovirus-mediated gene transfer of MMAC1/PTEN to ghoblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res 1999;59:2318-2323.
171. Wu RC, Li X, Schonthal AH. Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor. Mol Cell Biochem 2000;203:59-71.
172. Ramaswamy S, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999;96:2110-2115.
173. Schmidt-Weber CB, Wohlfahrt JG, Akdis CA, Blaser K. The phosphatidylinositol phosphatase PTEN is under control of costimulation and regulates proliferation in human T cells. Eur J Immunol 2002;32:1196-1204.
174. Suzuki A, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-1178.
175. Stocker H, Hafen E. Genetic control of cell size. Curr Opin Genet Dev 2000;10:529-535.
176. Shioi T, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000;19:2537-2548.
177. Crackower M, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002;110:737.
178. Condorelli G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002;99:12333-12338.
179. Kwon CH, et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001;29:404-411.
180. Backman SA, et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001;29:396-403.
181. Groszer M, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001;294:2186-2189.
182. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001;114:2375-2382.
183. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-390.
184. Liliental J, et al. Genetic deletion of the Pten rumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 2000;10:401-404.
185. Maier D, et al. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 1999;59:5479-5482.
186. Tsoukas CD, Grasis JA, Ching KA, Kawakami Y, Kawakami T. Itk/Emt: a link between T cell antigen receptor-mediated Ca2+ events and cytoskeletal reorganization. Trends Immunol 2001;22:17-20.
187. Tromans A. The attraction of lipids. Nature 2002;417:702.
188. Comer FI, Parent CA. PI 3-kinases and PTEN: how opposites chemoattract. Cell 2002;109:541-544.
189. Funamoto S, Meili R, Lee S, Parry L, Firtel RA. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell 2002;109:611-623.
190. Iijima M, Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell 2002;109:599-610.
191. Fox JA, Ung K, Tanlimco SG, Jirik FR. Disruption of a single Pten allele augments the chemotactic response of B lymphocytes to stromal cell-derived factor-1. J Immunol 2002;169:49-54.
192. Suzuki A, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001;14:523-534.
193. Sharp LL, Hedrick SM. Commitment to the CD4 lineage mediated by extracellular signal-related kinase mitogen-activated protein kinase and lck signaling. J Immunol 1999;163:6598-6605.
194. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 1999;274:32662-32666.
195. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 1998;92:3410-3415.
196. Wang X, Gjorloff-Wingren A, Saxena M, Pathan N, Reed JC, Mustelin T. The tumor suppressor PTEN regulates T cell surviral and antigen receptor signaling by acting as a phosphatidylinositol 3-phosphatase. J Immunol 2000;164:1934-1939.
197. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative 'null' and 'T' cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977;19:621-626.
198. Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ 2002;13:285-296.